News
-
-
-
COMMUNIQUÉ DE PRESSE
BioNxt Signs Strategic Agreement for Eurasian Commercialization Following Cladribine ODF Patent Grant in Eurasia and Europe
BioNxt Solutions Inc. signs LOI for commercialization of sublingual cladribine ODF in Eurasian Patent Organization member states, strengthening global IP position and pursuing licensing opportunities -
-
-
COMMUNIQUÉ DE PRESSE
BioNxt Announces Closing of Shares for Debt Settlement
BioNxt Solutions Inc. settles $2.7M debt with 6,008,883 common shares. Compensation shares issued to Canaccord Genuity Corp. for facilitating the debt settlement. Company focuses on drug delivery tech and pharmaceutical development -
-
-
COMMUNIQUÉ DE PRESSE
BioNxt Receives Milestone EPO Decision to Grant European Patent for Sublingual Cladribine Drug Delivery Technology for Multiple Sclerosis
BioNxt Solutions Inc. receives European Patent No. 4539857 for sublingual cladribine oral thin film drug delivery tech, advancing global IP rights in pharmaceutical sector -
